

October 30, 2012

Newsletter from Lytix Biopharma AS

### **Lytix Biopharma and ABG Sundal Collier signs collaboration agreement**

Unni Hjelmaas (CEO of Lytix Biopharma AS) and Peter Straume (partner at ABG Sundal Collier ASA, Norway) signed a collaboration agreement on Thursday October 18th 2012.

The agreement states that ABGSC will assist the company as financial advisor and strategic partner. ABGSC shall provide services in structuring, organization and planning of future financing of Lytix Biopharma.

Lytix Biopharma's former financial partner, Sparebank1 Nord-Norge Markets, has agreed to join as co-manager.

[Go to news on website](#)

### **Shareholder meetings**

Lytix Biopharma will host shareholder meetings in Tromsø, Harstad and Oslo, Norway in November 2012.

Information is send out separately.

[Go to news on website \(in Norwegian\)](#)

### **Lytix Biopharma AS**

**Lytix Biopharma AS** is a privately-owned pharmaceutical company focussed on anti-microbials and cancer therapeutics. Our mission is to improve human health. The Company develops novel drugs for the treatment of resistant bacterial and fungal infections, as well as first-in-class oncology treatments. This has resulted in an exciting pipeline - comprising both ultra-broad spectrum antimicrobials and an entirely new class of dual-action cancer therapeutics. For potential partners, we offer attractive co-development and licensing opportunities.

**Disclaimer.** Lytix Biopharma AS disclaims any expressed or implied warranties with respect to the information disclosed herein and is not liable for any damage or loss related to the accuracy, completeness or timeliness of the information. In particular, and without imposing any limitation to the above, any forward-looking statements and forecasts are based on high uncertainty, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on results of operations and the financial condition of Lytix Biopharma AS. Information is provided under Norwegian law.